[Chemotherapy of malignant melanoma. Results of a controlled clinical trial comparing vincristine + dacarbazin (DTIC) with and without duborimycin (author's transl)].
Adding duborimycin to the association of vincristine + DTIC in the treatment of malignant melanoma produces therapeutic results interesting but not statistically significant and not counter-balancing the toxic side effects. This study confirms the lack of positive results of polychemotherapy in melanoma as compared to treatment by an efficacious single drug therapy (DTIC); it also emphasizes the necessity of randomized studies so that valuable comparisons may be done.
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000008:administration & dosage* / Q000627:therapeutic use; D003630:Daunorubicin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D014226:Triazenes / Q000008:administration & dosage*; D014750:Vincristine / Q000008:administration & dosage* / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D014226:Triazenes; D014750:Vincristine; D003606:Dacarbazine; D003630:Daunorubicin
Chimiothérapie des mélanomes malins. Résultats d'un essai contrôlé comparant vincristine et dacarbazine (DTIC) avec ou sans duborimycine.